M2 PHARMA-December 12, 2017-Chronic Lymphocytic Leukemia
Patients Report Long-Term Benefits of Treatment with Imbruvica
USPRwire, Wed Oct 25 2017] This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia
(CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Session Title: Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia
Background: The established clinical staging systems (Rai/Binet) of chronic lymphocytic leukemia
(CLL) cannot accurately predict the appropriate treatment of patients in the earlier stages.
Objective: Chronic lymphocytic leukemia
(CLL) is a heterogeneous disease in terms of survival with and without treatment.
announced today that the anticancer agent TREAKISYM for Injection 100 mg (generic name: bendamustine hydrochloride, "TREAKISYM") has been approved in Japan for an additional indication of chronic lymphocytic leukemia
Global Markets Direct's, 'Chronic Lymphocytic Leukemia
(CLL) - Pipeline Review, H1 2016', provides an overview of the Chronic Lymphocytic Leukemia
(CLL) pipeline landscape.
M2 EQUITYBITES-March 7, 2016-AbbVie passes US FDA approval for IMBRUVICA (ibrutinib) for first-line treatment for patients with chronic lymphocytic leukemia
Being a mature B cell malignancy, the finding of monoclonal proteins is not unexpected in chronic lymphocytic leukemia
Chronic lymphocytic leukemia
(CLL) and diffuse large Bcell lymphoma (DLBCL) are 2 of the most common Bcell malignancies in adults, affecting almost 50 000 and more than 20 000 patients, respectively, in the United States each year.
UKPRwire, Fri Sep 13 2013] Global Markets Direct's, 'Refractory Chronic Lymphocytic Leukemia
(CLL) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline.
Introduction: Chronic lymphocytic leukemia
(CLL) is characterized by the progressive accumulation of B cells with mature appearance and a distinctive immunophenotype in peripheral blood, bone marrow, lymph nodes and other lymphoid tissues.